Page last updated: 2024-11-06

celgosivir

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

celgosivir: inhibits glycoprotein processing & the growth of HIVs [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID60734
CHEMBL ID2110737
SCHEMBL ID135812
MeSH IDM0192430

Synonyms (31)

Synonym
mbi-3253
vir-222
mdl-28574
mx-3253
bucast
celgosivir
[(1s,6s,7s,8r,8ar)-1,7,8-trihydroxy-1,2,3,5,6,7,8,8a-octahydroindolizin-6-yl] butanoate
mdl 28,574
b-cast
butanoic acid, (1s,6s,7s,8r,8ar)-octahydro-1,7,8-trihydroxy-6-indolizinyl ester
mdl 28574
6-o-butanoylcastanospermine
895vg117hn ,
butanoic acid, octahydro-1,7,8-trihydroxy-6-indolizinyl ester, (1s-(1alpha,6beta,7alpha,8beta,8abeta))-
unii-895vg117hn
(1s,6s,7s,8r,8ar)-octahydro-1,7,8-trihydroxy-6-indolizinyl butyrate
121104-96-9
celgosivir [inn]
celgosivir [who-dd]
butanoic acid, octahydro-1,7,8-trihydroxy-6-indolizinyl ester, (1s-(1.alpha.,6.beta.,7.alpha.,8.beta.,8a.beta.))-
SCHEMBL135812
CHEMBL2110737
DTXSID70153153
J-004448
HY-16134
AKOS030526324
CS-5634
DB06580
Q27270004
NCGC00510887-02
6-butyryl castanospermine

Research Excerpts

Overview

Celgosivir may prove to be a valuable component for combination therapy. It may help to prevent the apparition of drug resistance.

ExcerptReferenceRelevance
"Celgosivir may prove to be a valuable component for combination therapy and may help to prevent the apparition of drug resistance."( Celgosivir, an alpha-glucosidase I inhibitor for the potential treatment of HCV infection.
Durantel, D, 2009
)
2.52

Effects

ExcerptReferenceRelevance
"Celgosivir has a novel mechanism of action (ie, host-directed glycosylation), and demonstrates broad antiviral activity in vitro."( Celgosivir, an alpha-glucosidase I inhibitor for the potential treatment of HCV infection.
Durantel, D, 2009
)
2.52
"Celgosivir has a novel mechanism of action (ie, host-directed glycosylation), and demonstrates broad antiviral activity in vitro."( Celgosivir, an alpha-glucosidase I inhibitor for the potential treatment of HCV infection.
Durantel, D, 2009
)
2.52

Treatment

ExcerptReferenceRelevance
"Celgosivir treated mice showed enhanced survival, reduced viremia and robust immune response, as reflected by serum cytokine analysis."( Celgosivir treatment misfolds dengue virus NS1 protein, induces cellular pro-survival genes and protects against lethal challenge mouse model.
Connolly, JE; Low, J; Ooi, EE; Paradkar, PN; Rathore, AP; Sung, C; Tan, KH; Vasudevan, SG; Watanabe, S, 2011
)
2.53

Toxicity

ExcerptReferenceRelevance
" We noted similar incidences of adverse events between groups."( Efficacy and safety of celgosivir in patients with dengue fever (CELADEN): a phase 1b, randomised, double-blind, placebo-controlled, proof-of-concept trial.
Chan, WK; Cherng, BP; Cheung, YB; Chow, A; Chua, LT; Chung, JS; Connolly, J; Hibberd, ML; Hou, Y; Howe, S; Leo, YS; Low, JG; Lye, DC; Ng, LC; Ooi, EE; Rathore, APS; Sung, C; Tambayah, PA; Tan, BH; Tan, KH; Toh, L; Vasudevan, SG; Watanabe, S; Wei, Y; Wijaya, L, 2014
)
0.71
"Although generally safe and well tolerated, celgosivir does not seem to reduce viral load or fever burden in patients with dengue."( Efficacy and safety of celgosivir in patients with dengue fever (CELADEN): a phase 1b, randomised, double-blind, placebo-controlled, proof-of-concept trial.
Chan, WK; Cherng, BP; Cheung, YB; Chow, A; Chua, LT; Chung, JS; Connolly, J; Hibberd, ML; Hou, Y; Howe, S; Leo, YS; Low, JG; Lye, DC; Ng, LC; Ooi, EE; Rathore, APS; Sung, C; Tambayah, PA; Tan, BH; Tan, KH; Toh, L; Vasudevan, SG; Watanabe, S; Wei, Y; Wijaya, L, 2014
)
0.97

Compound-Compound Interactions

ExcerptReferenceRelevance
" MKC-442 was evaluated in combination with the nucleoside analogues AZT, ddI and ddC, the non-nucleoside RT inhibitor nevirapine, the HIV-1 proteinase inhibitor Ro-31-8959, and the alpha-glucosidase 1 inhibitor, MDL-28,574, using a cell viability assay."( The inhibition of human immunodeficiency virus type 1 in vitro by a non-nucleoside reverse transcriptase inhibitor MKC-442, alone and in combination with other anti-HIV compounds.
Brennan, TM; Bridges, CG; Leyda, JP; Taylor, DL; Tyms, AS, 1995
)
0.29

Bioavailability

ExcerptReferenceRelevance
" Celgosivir is well absorbed in vitro and in vivo, and is rapidly converted to castanospermine."( Celgosivir, an alpha-glucosidase I inhibitor for the potential treatment of HCV infection.
Durantel, D, 2009
)
2.71

Dosage Studied

ExcerptRelevanceReference
" With multiple dosing of mice, additive results were obtained, suggesting that multiple doses may be used to obtain higher concentrations of the compound in the target cells."( Uptake and metabolism of BuCast: a glycoprotein processing inhibitor and a potential anti-HIV drug.
Kang, MS, 1996
)
0.29
"Although the antiviral drug celgosivir, an α-glucosidase I inhibitor, is highly protective when given twice daily to AG129 mice infected with dengue virus, a similar regimen of twice daily dosing did not significantly reduce serum viral loads in patients in a recent clinical trial."( Optimizing celgosivir therapy in mouse models of dengue virus infection of serotypes 1 and 2: The search for a window for potential therapeutic efficacy.
Chan, KW; Dow, G; Low, JG; Ooi, EE; Vasudevan, SG; Watanabe, S, 2016
)
1.12
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID1631442Antiviral activity against Dengue virus 3 863 infected in BHK21 cells after 48 hrs by CFI assay2016Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12
The Medicinal Chemistry of Dengue Virus.
AID1631441Antiviral activity against Dengue virus 2 3295 infected in BHK21 cells after 48 hrs by CFI assay2016Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12
The Medicinal Chemistry of Dengue Virus.
AID1631440Antiviral activity against Dengue virus 1 2402 infected in BHK21 cells after 48 hrs by CFI assay2016Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12
The Medicinal Chemistry of Dengue Virus.
AID1631443Antiviral activity against Dengue virus 4 2270 infected in BHK21 cells after 48 hrs by CFI assay2016Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12
The Medicinal Chemistry of Dengue Virus.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (24)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's9 (37.50)18.2507
2000's3 (12.50)29.6817
2010's9 (37.50)24.3611
2020's3 (12.50)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 33.43

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index33.43 (24.57)
Research Supply Index3.33 (2.92)
Research Growth Index4.76 (4.65)
Search Engine Demand Index39.41 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (33.43)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (12.50%)5.53%
Reviews2 (8.33%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other19 (79.17%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]